A new horizon

Oxytocin as a novel therapeutic option for obesity and diabetes

Dongsheng Cai, Sudarshana Purkayastha

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The story of oxytocin (OXT) began long ago in evolutionary terms with its recognition as a classical neurohypophyseal hormone important for lactation and uterine contraction. With the recent discovery of its local actions in the brain, its previously unappreciated diverse functions in regulating social behaviors and metabolic physiology are emerging. In light of metabolic control, OXT has been shown to induce feeding restriction and body weight lowering through acting on brain regulatory regions, in particular the hypothalamus. Studies from pharmacologic interventions and genetic manipulations demonstrated that OXT can play significant roles in affecting glucose metabolism as well as insulin secretion and lipolysis, many of those functions being regulated both centrally and peripherally. Also excitingly, recent therapeutic success was obtained in clinical endeavor showing that OXT nasal spray effectively induced weight loss and metabolic improvement in human patients with obesity, thus further indicating OXT as a tangible drug target for treating obesity and metabolic complications. In addition to the native form, OXT-derived analogues have been found effective in inducing body weight control and glucose balance. Altogether, all recent advances in the understanding of OXT and metabolic regulation has laid a promising foundation for the therapeutic strategy of developing innovative OXT peptidyl drugs for the treatment of obesity and related metabolic diseases

Original languageEnglish (US)
JournalDrug Discovery Today: Disease Mechanisms
Volume10
Issue number1-2
DOIs
StatePublished - Jun 2013

Fingerprint

Oxytocin
Obesity
Therapeutics
Body Weight
Posterior Pituitary Hormones
Nasal Sprays
Glucose
Uterine Contraction
Genetic Engineering
Social Behavior
Lipolysis
Nucleic Acid Regulatory Sequences
Metabolic Diseases
Brain
Lactation
Pharmaceutical Preparations
Hypothalamus
Weight Loss
Insulin

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

A new horizon : Oxytocin as a novel therapeutic option for obesity and diabetes. / Cai, Dongsheng; Purkayastha, Sudarshana.

In: Drug Discovery Today: Disease Mechanisms, Vol. 10, No. 1-2, 06.2013.

Research output: Contribution to journalArticle

@article{a061adb4a93646a4806301f406f20207,
title = "A new horizon: Oxytocin as a novel therapeutic option for obesity and diabetes",
abstract = "The story of oxytocin (OXT) began long ago in evolutionary terms with its recognition as a classical neurohypophyseal hormone important for lactation and uterine contraction. With the recent discovery of its local actions in the brain, its previously unappreciated diverse functions in regulating social behaviors and metabolic physiology are emerging. In light of metabolic control, OXT has been shown to induce feeding restriction and body weight lowering through acting on brain regulatory regions, in particular the hypothalamus. Studies from pharmacologic interventions and genetic manipulations demonstrated that OXT can play significant roles in affecting glucose metabolism as well as insulin secretion and lipolysis, many of those functions being regulated both centrally and peripherally. Also excitingly, recent therapeutic success was obtained in clinical endeavor showing that OXT nasal spray effectively induced weight loss and metabolic improvement in human patients with obesity, thus further indicating OXT as a tangible drug target for treating obesity and metabolic complications. In addition to the native form, OXT-derived analogues have been found effective in inducing body weight control and glucose balance. Altogether, all recent advances in the understanding of OXT and metabolic regulation has laid a promising foundation for the therapeutic strategy of developing innovative OXT peptidyl drugs for the treatment of obesity and related metabolic diseases",
author = "Dongsheng Cai and Sudarshana Purkayastha",
year = "2013",
month = "6",
doi = "10.1016/j.ddmec.2013.05.006",
language = "English (US)",
volume = "10",
journal = "Drug Discovery Today: Disease Mechanisms",
issn = "1740-6765",
publisher = "Elsevier Limited",
number = "1-2",

}

TY - JOUR

T1 - A new horizon

T2 - Oxytocin as a novel therapeutic option for obesity and diabetes

AU - Cai, Dongsheng

AU - Purkayastha, Sudarshana

PY - 2013/6

Y1 - 2013/6

N2 - The story of oxytocin (OXT) began long ago in evolutionary terms with its recognition as a classical neurohypophyseal hormone important for lactation and uterine contraction. With the recent discovery of its local actions in the brain, its previously unappreciated diverse functions in regulating social behaviors and metabolic physiology are emerging. In light of metabolic control, OXT has been shown to induce feeding restriction and body weight lowering through acting on brain regulatory regions, in particular the hypothalamus. Studies from pharmacologic interventions and genetic manipulations demonstrated that OXT can play significant roles in affecting glucose metabolism as well as insulin secretion and lipolysis, many of those functions being regulated both centrally and peripherally. Also excitingly, recent therapeutic success was obtained in clinical endeavor showing that OXT nasal spray effectively induced weight loss and metabolic improvement in human patients with obesity, thus further indicating OXT as a tangible drug target for treating obesity and metabolic complications. In addition to the native form, OXT-derived analogues have been found effective in inducing body weight control and glucose balance. Altogether, all recent advances in the understanding of OXT and metabolic regulation has laid a promising foundation for the therapeutic strategy of developing innovative OXT peptidyl drugs for the treatment of obesity and related metabolic diseases

AB - The story of oxytocin (OXT) began long ago in evolutionary terms with its recognition as a classical neurohypophyseal hormone important for lactation and uterine contraction. With the recent discovery of its local actions in the brain, its previously unappreciated diverse functions in regulating social behaviors and metabolic physiology are emerging. In light of metabolic control, OXT has been shown to induce feeding restriction and body weight lowering through acting on brain regulatory regions, in particular the hypothalamus. Studies from pharmacologic interventions and genetic manipulations demonstrated that OXT can play significant roles in affecting glucose metabolism as well as insulin secretion and lipolysis, many of those functions being regulated both centrally and peripherally. Also excitingly, recent therapeutic success was obtained in clinical endeavor showing that OXT nasal spray effectively induced weight loss and metabolic improvement in human patients with obesity, thus further indicating OXT as a tangible drug target for treating obesity and metabolic complications. In addition to the native form, OXT-derived analogues have been found effective in inducing body weight control and glucose balance. Altogether, all recent advances in the understanding of OXT and metabolic regulation has laid a promising foundation for the therapeutic strategy of developing innovative OXT peptidyl drugs for the treatment of obesity and related metabolic diseases

UR - http://www.scopus.com/inward/record.url?scp=84880208775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880208775&partnerID=8YFLogxK

U2 - 10.1016/j.ddmec.2013.05.006

DO - 10.1016/j.ddmec.2013.05.006

M3 - Article

VL - 10

JO - Drug Discovery Today: Disease Mechanisms

JF - Drug Discovery Today: Disease Mechanisms

SN - 1740-6765

IS - 1-2

ER -